Review of biomarkers for response to immunotherapy in HNSCC microenvironment

Review of biomarkers for response to immunotherapy in HNSCC microenvironment

Head and neck squamous cell carcinoma are one of the most common types of cancer worldwide. Although a variety of treatment methods such as surgery, radiotherapy, chemotherapy, and targeted therapy are widely used in diagnosing and treating HNSCC, the survival prognosis of patients has not been sign...

Full description

Bibliographic Details
Main Authors:	Shaoshi Chen, Yifan Yang, Shizhi He, Meng Lian, Ru Wang, Jugao Fang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Oncology
Subjects:	head and neck squamous cell carcinoma tumor microenvironment PD-1 immunotherapy biomarker PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1037884/full

Similar Items

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
by: Weimin Lin, et al.
Published: (2018-11-01)

Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma
by: Shaokun Liu, et al.
Published: (2024-01-01)

Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
by: Yixiao Qin, et al.
Published: (2021-03-01)

Editorial: Immunology and Immunotherapy of Head and Neck Cancer
by: Niki Gavrielatou, et al.
Published: (2021-12-01)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
by: D. Evrard, et al.
Published: (2020-01-01)

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
by: Piero Giuseppe Meliante, et al.
Published: (2023-02-01)

Global research trends in immunotherapy for head and neck neoplasms: A scientometric study
by: Zhou Jiang, et al.
Published: (2023-04-01)

The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
by: Jiaming Su, et al.
Published: (2023-06-01)

The Role of Cytokinome in the HNSCC Tumor Microenvironment: A Narrative Review and Our Experience
by: Nerina Denaro, et al.
Published: (2022-11-01)

Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
by: Adam Khorasanchi, et al.
Published: (2022-10-01)

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
by: Che-Wei Wang, et al.
Published: (2024-02-01)

Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs
by: Simin Ahmadvand, et al.
Published: (2024-01-01)

Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies
by: Piero Giuseppe Meliante, et al.
Published: (2022-12-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
by: Zhanjun Guo, et al.
Published: (2022-03-01)

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis
by: Hsiang-Fong Kao, et al.
Published: (2022-11-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
by: Andrew Meci, et al.
Published: (2024-02-01)

Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study
by: Elena Guerini Rocco, et al.
Published: (2022-02-01)

Biomarkers for immunotherapy in esophageal cancer
by: Xuelian Wang, et al.
Published: (2023-05-01)

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
by: Jack M. Qian, et al.
Published: (2021-02-01)

Clinical implication of PD-L2 in the prognosis assessment of HNSCC immunotherapy
by: HUANG He, JU Houyu, YANG Wenyi, YAN Ming, REN Guoxin, HU Jingzhou
Published: (2023-06-01)

DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU)
by: Claire Lailler, et al.
Published: (2021-08-01)

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
by: Kate Clancy, et al.
Published: (2021-09-01)

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods
by: Yuxi Cheng, et al.
Published: (2024-02-01)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Edith Borcoman, et al.
Published: (2021-05-01)

Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma
by: Qimin Zhou, et al.
Published: (2022-11-01)

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
by: Habib Sadeghirad, et al.
Published: (2023-04-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
by: Alessandro Di Federico, et al.
Published: (2022-05-01)

Elucidating Hedgehog pathway's role in HNSCC progression: insights from a 6-gene signature
by: Yang Yang, et al.
Published: (2024-02-01)

A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC
by: Yinghe Ding, et al.
Published: (2023-01-01)

The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer
by: Jiajia Yuan, et al.
Published: (2022-07-01)

Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
by: Jerry Polesel, et al.
Published: (2021-11-01)

Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
by: Panagiota Economopoulou, et al.
Published: (2019-08-01)

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
by: Yui Hirata-Nozaki, et al.
Published: (2019-06-01)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
by: Fang Yang, et al.
Published: (2021-12-01)

Role of tumor microenvironment in cancer progression and therapeutic strategy
by: Qingjing Wang, et al.
Published: (2023-05-01)

CD73 in small extracellular vesicles derived from HNSCC defines tumour‐associated immunosuppression mediated by macrophages in the microenvironment
by: Tingwei Lu, et al.
Published: (2022-05-01)

Immunotherapies for advanced hepatocellular carcinoma
by: Li-Yang Sun, et al.
Published: (2023-03-01)